董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Evgeny Zaytsev | 男 | Independent Director | 58 | 未披露 | 224.42 | 2026-08-19 |
| Frederic Guerard | 男 | Independent Director | 53 | 6.25万美元 | 15.07 | 2026-08-19 |
| Robert N. Wilson | 男 | Chairman of the Board | 85 | 11.12万美元 | 175.64 | 2026-08-19 |
| Allan Shaw | 男 | Independent Director | 62 | 8.75万美元 | 10.15 | 2026-08-19 |
| A. Rachel Leheny | 女 | Chief Executive Officer and Director | 62 | 89.54万美元 | 169.81 | 2026-08-19 |
| Eric W. Roberts | 男 | Chief Business Officer, Director and Vice Chairman of the Board | 62 | 70.36万美元 | 164.70 | 2026-08-19 |
| Alan Glicklich | 男 | Independent Director | 65 | 10.52万美元 | 5.07 | 2026-08-19 |
| Evgeny Zaytsev | 男 | Independent Director | 58 | 未披露 | 未持股 | 2026-08-19 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Stephen Bardin | 男 | Chief Financial Officer | 36 | 未披露 | 未持股 | 2026-08-19 |
| A. Rachel Leheny | 女 | Chief Executive Officer and Director | 62 | 89.54万美元 | 169.81 | 2026-08-19 |
| Eric W. Roberts | 男 | Chief Business Officer, Director and Vice Chairman of the Board | 62 | 70.36万美元 | 164.70 | 2026-08-19 |
| Michael J. Dunn | 男 | Chief Operating Officer and President | 70 | 未披露 | 未持股 | 2026-08-19 |
| Sudarshan Hebbar | 男 | Chief Medical Officer | 61 | 76.33万美元 | 64.30 | 2026-08-19 |
| Kenneth A. Stauderman | 男 | Chief Scientific Officer | 73 | 未披露 | 未持股 | 2026-08-19 |
董事简历
中英对照 | 中文 | 英文- Evgeny Zaytsev
-
Evgeny Zaytsev，他曾一直担任公司的董事（2014年8月以来）。他曾一直担任RMI Partners公司的总裁、首席执行官和管理合伙人（2013年5月以来），以及RMI Partners公司的总裁兼首席执行官（2013年11月以来）。他也曾担任Helix Ventures公司（他共同创立的公司，投资于新型治疗机会）的普通合伙人（2009年7月以来）。此前，他曾担任Asset Management Company（硅谷最古老的风险投资公司之一）的合伙人（从2002年到2009年）。他持有the Altai State Medical University的医学博士学位和哲学博士学位，以及the Stanford Graduate School of Business的工商管理硕士学位。
Evgeny Zaytsev,Dr. Zaytsev has served as a director of company since August 2014. Dr. Zaytsev has served as a general partner at Helix Ventures, which he co-founded to exclusively invest in novel therapeutic opportunities, since July 2009. Dr. Zaytsev also served as a managing partner of RMI Partners LLC from May 2013 to March 2018 and as the President and Chief Executive Officer of RMI Partners Inc. from November 2013 to March 2018. Previously Dr. Zaytsev was a partner at Asset Management Company, one of the oldest venture firms in Silicon Valley, from 2002 to 2009. Dr. Zaytsev received his M.D. degree and Ph.D. degree from the Altai State Medical University and his M.B.A. degree from the Stanford Graduate School of Business. - Evgeny Zaytsev，他曾一直担任公司的董事（2014年8月以来）。他曾一直担任RMI Partners公司的总裁、首席执行官和管理合伙人（2013年5月以来），以及RMI Partners公司的总裁兼首席执行官（2013年11月以来）。他也曾担任Helix Ventures公司（他共同创立的公司，投资于新型治疗机会）的普通合伙人（2009年7月以来）。此前，他曾担任Asset Management Company（硅谷最古老的风险投资公司之一）的合伙人（从2002年到2009年）。他持有the Altai State Medical University的医学博士学位和哲学博士学位，以及the Stanford Graduate School of Business的工商管理硕士学位。
- Evgeny Zaytsev,Dr. Zaytsev has served as a director of company since August 2014. Dr. Zaytsev has served as a general partner at Helix Ventures, which he co-founded to exclusively invest in novel therapeutic opportunities, since July 2009. Dr. Zaytsev also served as a managing partner of RMI Partners LLC from May 2013 to March 2018 and as the President and Chief Executive Officer of RMI Partners Inc. from November 2013 to March 2018. Previously Dr. Zaytsev was a partner at Asset Management Company, one of the oldest venture firms in Silicon Valley, from 2002 to 2009. Dr. Zaytsev received his M.D. degree and Ph.D. degree from the Altai State Medical University and his M.B.A. degree from the Stanford Graduate School of Business.
- Frederic Guerard
-
Frederic Guerard自2019年2月起担任我们的总裁兼首席执行官兼董事会成员。1999年至2019年2月，Guerard博士在跨国制药公司Novartis AG担任重要领导职务，包括2016年4月至2019年2月，担任诺华制药公司Alcon Vision LLC的全球眼科业务特许经营主管，2015年5月至2016年4月，担任英国和爱尔兰的董事总经理（2012年7月至2015年4月），以及澳大利亚和新西兰的国家总裁兼董事总经理（2009年4月至2012年7月）。Guerard博士持有Pharm.D.以及法国鲁昂大学（University of Rouen）生物和医学科学硕士学位和巴黎高等商学院（HEC Paris）市场营销硕士学位。
Frederic Guerard has served as a member of the Board of Directors since March 2023. Prior to that, he served as the President, Chief Executive Officer and member of the board of directors of Graybug Vision, Inc. from February 2019 to March 2023. Dr. Guerard has served as the President, Chief Executive Officer and member of the board of directors of Qlaris Bio, Inc. since March 2026. From October 2023 to September 2025, he served as the Chief Executive Officer and a director of Opthea Limited. From 1999 to February 2019, Dr. Guerard held key leadership roles at Novartis AG, a multinational pharmaceutical company, including Worldwide Business Franchise Head of Ophthalmology from April 2016 to February 2019, Global Franchise Head of Pharmaceuticals at Alcon Laboratories, a Novartis company, from May 2015 to April 2016, Managing Director of the United Kingdom and Ireland from July 2012 to April 2015, and Country President and Managing Director of Australia and New Zealand from April 2009 to July 2012, among others. He has served on the boards of directors at Lenz Therapeutics since September 2021 where he serves as a member of the compensation committee of the board of directors and the audit committee of the board of directors, Spiral Therapeutics since April 2023 and Unither Pharmaceuticals since July 2023. Dr. Guerard holds a Pharm.D. and a Master of Biological and Medical Sciences from the University of Rouen, France and a Master of Marketing from HEC Paris. - Frederic Guerard自2019年2月起担任我们的总裁兼首席执行官兼董事会成员。1999年至2019年2月，Guerard博士在跨国制药公司Novartis AG担任重要领导职务，包括2016年4月至2019年2月，担任诺华制药公司Alcon Vision LLC的全球眼科业务特许经营主管，2015年5月至2016年4月，担任英国和爱尔兰的董事总经理（2012年7月至2015年4月），以及澳大利亚和新西兰的国家总裁兼董事总经理（2009年4月至2012年7月）。Guerard博士持有Pharm.D.以及法国鲁昂大学（University of Rouen）生物和医学科学硕士学位和巴黎高等商学院（HEC Paris）市场营销硕士学位。
- Frederic Guerard has served as a member of the Board of Directors since March 2023. Prior to that, he served as the President, Chief Executive Officer and member of the board of directors of Graybug Vision, Inc. from February 2019 to March 2023. Dr. Guerard has served as the President, Chief Executive Officer and member of the board of directors of Qlaris Bio, Inc. since March 2026. From October 2023 to September 2025, he served as the Chief Executive Officer and a director of Opthea Limited. From 1999 to February 2019, Dr. Guerard held key leadership roles at Novartis AG, a multinational pharmaceutical company, including Worldwide Business Franchise Head of Ophthalmology from April 2016 to February 2019, Global Franchise Head of Pharmaceuticals at Alcon Laboratories, a Novartis company, from May 2015 to April 2016, Managing Director of the United Kingdom and Ireland from July 2012 to April 2015, and Country President and Managing Director of Australia and New Zealand from April 2009 to July 2012, among others. He has served on the boards of directors at Lenz Therapeutics since September 2021 where he serves as a member of the compensation committee of the board of directors and the audit committee of the board of directors, Spiral Therapeutics since April 2023 and Unither Pharmaceuticals since July 2023. Dr. Guerard holds a Pharm.D. and a Master of Biological and Medical Sciences from the University of Rouen, France and a Master of Marketing from HEC Paris.
- Robert N. Wilson
-
Robert N. Wilson，自2020年11月起担任CalciMedica董事会成员。2005年至2016年，他担任Mevion Medical Systems, Inc.的董事会主席。他也是Hess Corporation的董事会成员（1991年至2015年），Charles Schwab Corporation的董事会成员（2003年至2020年），以及其他私人公司的董事。从2004年到2007年，他担任Caxton Health Holdings的董事长。从1989年到2003年，他也是Johnson & Johnson的董事会副主席。他持有Georgetown College的学士学位和Columbia University的行政管理学位。
Robert N. Wilson has served as a member of the Board of Directors since March 2023. Prior to that, he served on Private CalciMedica's board of directors from November 2020 to March 2023. Mr. Wilson served as chairman of the board of directors of Mevion Medical Systems, Inc. from 2005 to 2016. Mr. Wilson was also a member of the board of directors of Hess Corporation from 1991 to 2015, and a member of the board of directors of Charles Schwab Corporation from 2003 to 2020, as well as a director of other private companies. Mr. Wilson was chairman of Caxton Health Holdings from 2004 to 2007. He was also vice chairman of the board of directors of Johnson & Johnson from 1989 until 2003. Mr. Wilson holds a B.A. from Georgetown College and an Executive Management degree from Columbia University. - Robert N. Wilson，自2020年11月起担任CalciMedica董事会成员。2005年至2016年，他担任Mevion Medical Systems, Inc.的董事会主席。他也是Hess Corporation的董事会成员（1991年至2015年），Charles Schwab Corporation的董事会成员（2003年至2020年），以及其他私人公司的董事。从2004年到2007年，他担任Caxton Health Holdings的董事长。从1989年到2003年，他也是Johnson & Johnson的董事会副主席。他持有Georgetown College的学士学位和Columbia University的行政管理学位。
- Robert N. Wilson has served as a member of the Board of Directors since March 2023. Prior to that, he served on Private CalciMedica's board of directors from November 2020 to March 2023. Mr. Wilson served as chairman of the board of directors of Mevion Medical Systems, Inc. from 2005 to 2016. Mr. Wilson was also a member of the board of directors of Hess Corporation from 1991 to 2015, and a member of the board of directors of Charles Schwab Corporation from 2003 to 2020, as well as a director of other private companies. Mr. Wilson was chairman of Caxton Health Holdings from 2004 to 2007. He was also vice chairman of the board of directors of Johnson & Johnson from 1989 until 2003. Mr. Wilson holds a B.A. from Georgetown College and an Executive Management degree from Columbia University.
- Allan Shaw
-
Allan Shaw，自2021年10月起担任CalciMedica董事会成员。自2017年9月以来，肖先生一直担任生物制药公司的特别顾问和咨询首席财务官。2016年1月至2017年2月，肖先生担任Syndax Pharmaceuticals, Inc.的首席财务官兼财务主管，该公司是一家上市的临床阶段生物制药公司。Shaw先生还曾担任多家公司的首席财务官，包括2009年10月至2011年7月的NewLead Holdings Ltd.、2002年11月至2004年5月的Serono S.A.和1994年11月至2002年6月的Viatel，Inc.。肖先生曾于2011年12月至2015年3月担任Alvarez & Marsal LLC的董事总经理，并于2005年至2009年担任Shaw Strategic Capital LLC的创始人和高级董事总经理。自2020年5月以来，肖先生一直担任上市生物技术公司Portage Biotech Inc.的首席财务官。肖先生于2020年1月至2022年8月担任Blue Water Vaccines公司董事会成员。2015年9月至2019年10月，他是前上市生物制药公司VIVUS，Inc.的董事会成员，2013年10月至2016年6月，他是Akari Therapeutics, Plc的董事会成员。（前身为Celsus Therapeutics，plc），一家公开上市的生物制药公司。邵逸夫也是其他多家私营公司的董事。Shaw先生拥有纽约州立大学（奥斯威戈学院）应用科学和会计学学士学位，是纽约州的注册会计师。
Allan Shaw has served as a member of the Board of Directors since March 2023. Prior to that, he served on CalciMedica Subsidiary, Inc.'s (formerly CalciMedica, Inc.) ("Private CalciMedica") board of directors from October 2021 to March 2023 prior to its merger with the Company (formerly Graybug Vision, Inc.) in March 2023. Since September 2017, Mr. Shaw has served as a special advisor and consulting chief financial officer to biopharmaceutical companies. Mr. Shaw previously served as the chief financial officer of Portage Biotech Inc., a publicly traded biotechnology company, from May 2020 to September 2024. He has also served on the board of directors of Evecxia Therapeutics, Inc. since October 2023. From January 2016 to February 2017, Mr. Shaw served as chief financial officer and treasurer of Syndax Pharmaceuticals, Inc., a publicly traded clinical stage biopharmaceutical company. Mr. Shaw also previously served as chief financial officer of various companies including NewLead Holdings Ltd. from October 2009 to July 2011, Serono S.A. from November 2002 to May 2004, and Viatel, Inc. from November 1994 to June 2002. Mr. Shaw previously served as managing director of Alvarez & Marsal LLC from December 2011 to March 2015 and as founder and senior managing director at Shaw Strategic Capital LLC from 2005 to 2009. Mr. Shaw served as a member of the board of directors of Blue Water Vaccines, Inc. from January 2020 to August 2022. From September 2015 to October 2019, he was a member of the board of directors of VIVUS, Inc., a former publicly traded biopharmaceutical company, and,from October 2013 to June 2016, he was a member of the board of directors of Akari Therapeutics, Plc.(formerly Celsus Therapeutics, plc), a publicly traded biopharmaceutical company. Mr. Shaw was also a director of various other private companies. Mr. Shaw holds a B.S. in Applied Science and Accounting from the State University of New York (Oswego College) and is a certified public accountant in the State of New York. - Allan Shaw，自2021年10月起担任CalciMedica董事会成员。自2017年9月以来，肖先生一直担任生物制药公司的特别顾问和咨询首席财务官。2016年1月至2017年2月，肖先生担任Syndax Pharmaceuticals, Inc.的首席财务官兼财务主管，该公司是一家上市的临床阶段生物制药公司。Shaw先生还曾担任多家公司的首席财务官，包括2009年10月至2011年7月的NewLead Holdings Ltd.、2002年11月至2004年5月的Serono S.A.和1994年11月至2002年6月的Viatel，Inc.。肖先生曾于2011年12月至2015年3月担任Alvarez & Marsal LLC的董事总经理，并于2005年至2009年担任Shaw Strategic Capital LLC的创始人和高级董事总经理。自2020年5月以来，肖先生一直担任上市生物技术公司Portage Biotech Inc.的首席财务官。肖先生于2020年1月至2022年8月担任Blue Water Vaccines公司董事会成员。2015年9月至2019年10月，他是前上市生物制药公司VIVUS，Inc.的董事会成员，2013年10月至2016年6月，他是Akari Therapeutics, Plc的董事会成员。（前身为Celsus Therapeutics，plc），一家公开上市的生物制药公司。邵逸夫也是其他多家私营公司的董事。Shaw先生拥有纽约州立大学（奥斯威戈学院）应用科学和会计学学士学位，是纽约州的注册会计师。
- Allan Shaw has served as a member of the Board of Directors since March 2023. Prior to that, he served on CalciMedica Subsidiary, Inc.'s (formerly CalciMedica, Inc.) ("Private CalciMedica") board of directors from October 2021 to March 2023 prior to its merger with the Company (formerly Graybug Vision, Inc.) in March 2023. Since September 2017, Mr. Shaw has served as a special advisor and consulting chief financial officer to biopharmaceutical companies. Mr. Shaw previously served as the chief financial officer of Portage Biotech Inc., a publicly traded biotechnology company, from May 2020 to September 2024. He has also served on the board of directors of Evecxia Therapeutics, Inc. since October 2023. From January 2016 to February 2017, Mr. Shaw served as chief financial officer and treasurer of Syndax Pharmaceuticals, Inc., a publicly traded clinical stage biopharmaceutical company. Mr. Shaw also previously served as chief financial officer of various companies including NewLead Holdings Ltd. from October 2009 to July 2011, Serono S.A. from November 2002 to May 2004, and Viatel, Inc. from November 1994 to June 2002. Mr. Shaw previously served as managing director of Alvarez & Marsal LLC from December 2011 to March 2015 and as founder and senior managing director at Shaw Strategic Capital LLC from 2005 to 2009. Mr. Shaw served as a member of the board of directors of Blue Water Vaccines, Inc. from January 2020 to August 2022. From September 2015 to October 2019, he was a member of the board of directors of VIVUS, Inc., a former publicly traded biopharmaceutical company, and,from October 2013 to June 2016, he was a member of the board of directors of Akari Therapeutics, Plc.(formerly Celsus Therapeutics, plc), a publicly traded biopharmaceutical company. Mr. Shaw was also a director of various other private companies. Mr. Shaw holds a B.S. in Applied Science and Accounting from the State University of New York (Oswego College) and is a certified public accountant in the State of New York.
- A. Rachel Leheny
-
A. Rachel Leheny，自2019年9月起担任CalciMedica首席执行官和董事会成员。Leheny博士是CalciMedica的前董事会主席。Leheny博士自2012年以来一直是Valence Life Sciences的创始董事总经理。Leheny博士是Dalcor Pharmaceuticals的董事会成员，曾在Anthera制药公司和Corthera公司担任董事。此外，2006年6月至2014年3月，Leheny博士担任Caxton Advantage Venture Partners的创始董事总经理。2000年4月至2002年6月，她担任雷曼兄弟生物技术研究团队的负责人。1998年4月至2000年4月，Leheny博士领导瑞银华宝的生物技术研究团队，在此之前的1993年4月至1998年4月，她在Hambrecht & Quist工作，担任董事总经理和高级生物技术分析师。2007年，Leheny博士成为Clearity基金会的创始董事会成员，并在2015年3月至2017年2月期间担任Clearity的临时首席运营官。Leheny博士拥有哈佛大学化学学士学位和哥伦比亚大学化学博士学位。她在加州大学伯克利分校做博士后工作，在那里她是美国国立卫生研究院的研究员和讲师。
A. Rachel Leheny has served as Calcimedica, Inc.'s Chief Executive Officer and a member of the Board of Directors since March 2023. Prior to that, she served as Private CalciMedica's Chief Executive Officer and a member of its board of directors from September 2019 to March 2023. Dr. Leheny has been a founding managing director of Valence Life Sciences since 2012. Dr. Leheny previously served on the board of directors of Dalcor Pharmaceuticals from June 2020 to January 2024 and previously served on the boards of directors of Anthera Pharmaceuticals, Inc. and Corthera, Inc. Additionally, from June 2006 to March 2014, Dr. Leheny served as a founding managing director of Caxton Advantage Venture Partners. From April 2000 to June 2002, she was head of the biotechnology research team at Lehman Brothers. From April 1998 to April 2000, Dr. Leheny headed the biotechnology research team at UBS Warburg and, before that, from April 1993 to April 1998, she worked at Hambrecht & Quist, as managing director and senior biotechnology analyst. In 2007, Dr. Leheny became a founding board member of the Clearity Foundation and served as interim chief operating officer of Clearity from March 2015 to February 2017. Dr. Leheny holds an A.B. in Chemistry from Harvard University and a Ph.D. in Chemistry from Columbia University. She did post doctoral work at the University of California at Berkeley, where she was a National Institutes of Health fellow and lecturer. - A. Rachel Leheny，自2019年9月起担任CalciMedica首席执行官和董事会成员。Leheny博士是CalciMedica的前董事会主席。Leheny博士自2012年以来一直是Valence Life Sciences的创始董事总经理。Leheny博士是Dalcor Pharmaceuticals的董事会成员，曾在Anthera制药公司和Corthera公司担任董事。此外，2006年6月至2014年3月，Leheny博士担任Caxton Advantage Venture Partners的创始董事总经理。2000年4月至2002年6月，她担任雷曼兄弟生物技术研究团队的负责人。1998年4月至2000年4月，Leheny博士领导瑞银华宝的生物技术研究团队，在此之前的1993年4月至1998年4月，她在Hambrecht & Quist工作，担任董事总经理和高级生物技术分析师。2007年，Leheny博士成为Clearity基金会的创始董事会成员，并在2015年3月至2017年2月期间担任Clearity的临时首席运营官。Leheny博士拥有哈佛大学化学学士学位和哥伦比亚大学化学博士学位。她在加州大学伯克利分校做博士后工作，在那里她是美国国立卫生研究院的研究员和讲师。
- A. Rachel Leheny has served as Calcimedica, Inc.'s Chief Executive Officer and a member of the Board of Directors since March 2023. Prior to that, she served as Private CalciMedica's Chief Executive Officer and a member of its board of directors from September 2019 to March 2023. Dr. Leheny has been a founding managing director of Valence Life Sciences since 2012. Dr. Leheny previously served on the board of directors of Dalcor Pharmaceuticals from June 2020 to January 2024 and previously served on the boards of directors of Anthera Pharmaceuticals, Inc. and Corthera, Inc. Additionally, from June 2006 to March 2014, Dr. Leheny served as a founding managing director of Caxton Advantage Venture Partners. From April 2000 to June 2002, she was head of the biotechnology research team at Lehman Brothers. From April 1998 to April 2000, Dr. Leheny headed the biotechnology research team at UBS Warburg and, before that, from April 1993 to April 1998, she worked at Hambrecht & Quist, as managing director and senior biotechnology analyst. In 2007, Dr. Leheny became a founding board member of the Clearity Foundation and served as interim chief operating officer of Clearity from March 2015 to February 2017. Dr. Leheny holds an A.B. in Chemistry from Harvard University and a Ph.D. in Chemistry from Columbia University. She did post doctoral work at the University of California at Berkeley, where she was a National Institutes of Health fellow and lecturer.
- Eric W. Roberts
-
Eric W. Roberts，自2020年5月起担任CalciMedica首席商务官和董事会成员，并担任副董事长。自2012年以来，罗伯茨一直是Valence Life Sciences的创始董事总经理。罗伯茨先生还是Valence Investments SPV IV、Valence Investments SPV V和Valence Investments SPV VI的创始成员。此外，从2006年6月至2019年12月，罗伯茨先生担任Caxton Advantage Venture Partners的创始董事总经理。从2015年到2019年10月，罗伯茨在VIVUS，Inc.的董事会任职，该公司曾是一家上市生物制药公司。罗伯茨先生曾于2012年6月担任Invuity公司董事会成员，直至2018年10月将其出售给史赛克公司，并于2008年7月担任Gemin X Pharmaceuticals公司董事会成员，直至2012年3月将其出售给Cephalon, Inc.（现为梯瓦制药有限公司）。从1986年到2004年，罗伯茨担任过多种投资银行家的职务，包括2000年4月至2004年1月担任雷曼兄弟医疗保健投资银行部门联席主管，1989年4月至2000年4月担任Dillon，Read & Co. Inc.董事总经理兼合伙人，1986年6月至1989年4月担任花旗公司并购和风险投资部门成员。罗伯茨拥有宾夕法尼亚大学沃顿商学院经济学学士学位。
Eric W. Roberts has served as Calcimedica, Inc.'s Chief Business Officer and member of the Board of Directors since March 2023. Prior to that, he served as Private CalciMedica's Chief Business Officer and a member of its board of directors and its vice chairman from May 2020 to March 2023. Mr. Roberts has been a founding managing director of Valence Life Sciences since 2012. Mr. Roberts is also a founding member of Valence Investments SPV IV, Valence Investments SPV V and Valence Investments SPV VI. Additionally, from June 2006 to December 2019, Mr. Roberts served as a founding managing director of Caxton Advantage Venture Partners. From June 2015 to October 2019, Mr. Roberts served on the board of directors of VIVUS, Inc., a former publicly traded biopharmaceutical company. Mr. Roberts previously served as a member of the board of directors of Invuity, Inc. from June 2012 until its sale to Stryker Corporation in October 2018 and as a member of the board of directors of Gemin X Pharmaceuticals, Inc. from July 2008 until its sale to Cephalon, Inc. (now Teva Pharmaceutical Industries Ltd.) in March 2012. From 1986 to 2004, Mr. Roberts served in a variety of roles as an investment banker, including as co head of the healthcare investment banking group at Lehman Brothers from April 2000 to January 2004, managing director and partner at Dillon, Read & Co. Inc. from April 1989 to April 2000 and a member of Citicorp's mergers and venture capital groups from June 1986 to April 1989. Mr. Roberts holds a B.S. in Economics from The Wharton School of the University of Pennsylvania. - Eric W. Roberts，自2020年5月起担任CalciMedica首席商务官和董事会成员，并担任副董事长。自2012年以来，罗伯茨一直是Valence Life Sciences的创始董事总经理。罗伯茨先生还是Valence Investments SPV IV、Valence Investments SPV V和Valence Investments SPV VI的创始成员。此外，从2006年6月至2019年12月，罗伯茨先生担任Caxton Advantage Venture Partners的创始董事总经理。从2015年到2019年10月，罗伯茨在VIVUS，Inc.的董事会任职，该公司曾是一家上市生物制药公司。罗伯茨先生曾于2012年6月担任Invuity公司董事会成员，直至2018年10月将其出售给史赛克公司，并于2008年7月担任Gemin X Pharmaceuticals公司董事会成员，直至2012年3月将其出售给Cephalon, Inc.（现为梯瓦制药有限公司）。从1986年到2004年，罗伯茨担任过多种投资银行家的职务，包括2000年4月至2004年1月担任雷曼兄弟医疗保健投资银行部门联席主管，1989年4月至2000年4月担任Dillon，Read & Co. Inc.董事总经理兼合伙人，1986年6月至1989年4月担任花旗公司并购和风险投资部门成员。罗伯茨拥有宾夕法尼亚大学沃顿商学院经济学学士学位。
- Eric W. Roberts has served as Calcimedica, Inc.'s Chief Business Officer and member of the Board of Directors since March 2023. Prior to that, he served as Private CalciMedica's Chief Business Officer and a member of its board of directors and its vice chairman from May 2020 to March 2023. Mr. Roberts has been a founding managing director of Valence Life Sciences since 2012. Mr. Roberts is also a founding member of Valence Investments SPV IV, Valence Investments SPV V and Valence Investments SPV VI. Additionally, from June 2006 to December 2019, Mr. Roberts served as a founding managing director of Caxton Advantage Venture Partners. From June 2015 to October 2019, Mr. Roberts served on the board of directors of VIVUS, Inc., a former publicly traded biopharmaceutical company. Mr. Roberts previously served as a member of the board of directors of Invuity, Inc. from June 2012 until its sale to Stryker Corporation in October 2018 and as a member of the board of directors of Gemin X Pharmaceuticals, Inc. from July 2008 until its sale to Cephalon, Inc. (now Teva Pharmaceutical Industries Ltd.) in March 2012. From 1986 to 2004, Mr. Roberts served in a variety of roles as an investment banker, including as co head of the healthcare investment banking group at Lehman Brothers from April 2000 to January 2004, managing director and partner at Dillon, Read & Co. Inc. from April 1989 to April 2000 and a member of Citicorp's mergers and venture capital groups from June 1986 to April 1989. Mr. Roberts holds a B.S. in Economics from The Wharton School of the University of Pennsylvania.
- Alan Glicklich
-
Alan Glicklich自2025年1月起担任Calcimedica，Inc.董事会成员。Glicklich博士自2026年2月起担任Lonestar Medicines的首席医疗官。2023年7月至2025年10月，Glicklich博士担任Nuvig Therapeutics，Inc.的首席医疗官，这是一家临床阶段的生物技术公司，正在推进针对慢性炎症和自身免疫性疾病的免疫疗法管道，在此之前，他于2022年5月至2023年7月担任Nuvig Therapeutics，Inc.的独立临床顾问。他于2020年5月至2022年3月期间担任Chinook Therapeutics, Inc.（“Chinook”）的首席医疗官，专注于治疗罕见的慢性肾脏疾病的生物制剂和小分子药物。在Chinook，他建立了临床开发、临床运营、医疗事务、生物识别、监管和药物警戒团队，并设计和运营了一项成功的阿曲森坦治疗IgA肾病的3期注册研究和跨罕见慢性肾病适应症的多个早期阶段研究。在加入Chinook之前，Glicklich博士于2015年6月至2020年4月担任Bird Rock Bio，Inc.的首席医疗官，专注于炎症和纤维化疾病的单克隆抗体开发。在加入Bird Rock，Inc.之前，Glicklich博士是阿里那制药公司的临床开发副总裁，在那里他设计并运营了肺动脉高压的2期ralinepeg项目和溃疡性结肠炎的etrasimod 2期项目。在其职业生涯的早期，Glicklich博士曾在BMS、赛诺菲 Aventis和再生元制药任职。Glicklich博士拥有芝加哥大学生物学学士学位、威斯康辛大学医学博士学位和埃默里大学Goizueta商学院MBA学位。
Alan Glicklich has served as the Chief Medical Officer of Lonestar Medicines since February 2026. From July 2023 to October 2025, Dr. Glicklich served as the Chief Medical Officer of Nuvig Therapeutics, Inc., a clinical stage biotechnology company advancing a pipeline of immune therapeutics for chronic inflammatory and autoimmune diseases, and, prior to that, he served as an independent clinical consultant to Nuvig Therapeutics, Inc. from May 2022 to July 2023. He served as Chief Medical Officer of Chinook Therapeutics, Inc. ("Chinook") from May 2020 to March 2022 where he focused on biologics and small molecules for rare, chronic kidney diseases. At Chinook, he built the clinical development, clinical operations, medical affairs, biometrics, regulatory, and pharmacovigilance teams, and designed and operationalized a successful Phase 3 registrational study for atrasentan in IgA nephropathy and multiple earlier phase studies across rare chronic kidney disease indications. Prior to Chinook, Dr. Glicklich served as Chief Medical Officer at Bird Rock Bio, Inc. from June 2015 to April 2020, focusing on monoclonal antibody development for inflammatory and fibrotic diseases. Prior to Bird Rock,Inc., Dr. Glicklich was Vice President of Clinical Development at Arena Pharmaceuticals, Inc. where he designed and operationalized the Phase 2 ralinepeg program in pulmonary artery hypertension and the etrasimod Phase 2 program in ulcerative colitis. Earlier in his career Dr. Glicklich held positions at BMS, Sanofi Aventis, and Regeneron. Dr. Glicklich holds a B.A. in biology from the University of Chicago, an M.D. from the University of Wisconsin, and an MBA from the Emory University Goizueta School of Business. - Alan Glicklich自2025年1月起担任Calcimedica，Inc.董事会成员。Glicklich博士自2026年2月起担任Lonestar Medicines的首席医疗官。2023年7月至2025年10月，Glicklich博士担任Nuvig Therapeutics，Inc.的首席医疗官，这是一家临床阶段的生物技术公司，正在推进针对慢性炎症和自身免疫性疾病的免疫疗法管道，在此之前，他于2022年5月至2023年7月担任Nuvig Therapeutics，Inc.的独立临床顾问。他于2020年5月至2022年3月期间担任Chinook Therapeutics, Inc.（“Chinook”）的首席医疗官，专注于治疗罕见的慢性肾脏疾病的生物制剂和小分子药物。在Chinook，他建立了临床开发、临床运营、医疗事务、生物识别、监管和药物警戒团队，并设计和运营了一项成功的阿曲森坦治疗IgA肾病的3期注册研究和跨罕见慢性肾病适应症的多个早期阶段研究。在加入Chinook之前，Glicklich博士于2015年6月至2020年4月担任Bird Rock Bio，Inc.的首席医疗官，专注于炎症和纤维化疾病的单克隆抗体开发。在加入Bird Rock，Inc.之前，Glicklich博士是阿里那制药公司的临床开发副总裁，在那里他设计并运营了肺动脉高压的2期ralinepeg项目和溃疡性结肠炎的etrasimod 2期项目。在其职业生涯的早期，Glicklich博士曾在BMS、赛诺菲 Aventis和再生元制药任职。Glicklich博士拥有芝加哥大学生物学学士学位、威斯康辛大学医学博士学位和埃默里大学Goizueta商学院MBA学位。
- Alan Glicklich has served as the Chief Medical Officer of Lonestar Medicines since February 2026. From July 2023 to October 2025, Dr. Glicklich served as the Chief Medical Officer of Nuvig Therapeutics, Inc., a clinical stage biotechnology company advancing a pipeline of immune therapeutics for chronic inflammatory and autoimmune diseases, and, prior to that, he served as an independent clinical consultant to Nuvig Therapeutics, Inc. from May 2022 to July 2023. He served as Chief Medical Officer of Chinook Therapeutics, Inc. ("Chinook") from May 2020 to March 2022 where he focused on biologics and small molecules for rare, chronic kidney diseases. At Chinook, he built the clinical development, clinical operations, medical affairs, biometrics, regulatory, and pharmacovigilance teams, and designed and operationalized a successful Phase 3 registrational study for atrasentan in IgA nephropathy and multiple earlier phase studies across rare chronic kidney disease indications. Prior to Chinook, Dr. Glicklich served as Chief Medical Officer at Bird Rock Bio, Inc. from June 2015 to April 2020, focusing on monoclonal antibody development for inflammatory and fibrotic diseases. Prior to Bird Rock,Inc., Dr. Glicklich was Vice President of Clinical Development at Arena Pharmaceuticals, Inc. where he designed and operationalized the Phase 2 ralinepeg program in pulmonary artery hypertension and the etrasimod Phase 2 program in ulcerative colitis. Earlier in his career Dr. Glicklich held positions at BMS, Sanofi Aventis, and Regeneron. Dr. Glicklich holds a B.A. in biology from the University of Chicago, an M.D. from the University of Wisconsin, and an MBA from the Emory University Goizueta School of Business.
- Evgeny Zaytsev
-
Evgeny Zaytsev自2026年7月起担任董事会成员。他目前担任多家私营生物技术和医疗技术公司的董事会成员。自2020年4月起，Zaytsev博士担任白令资本的联合创始人和管理合伙人。2020年5月至2021年9月，Zaytsev博士为Altesa BioSciences，Inc.的联合创始人兼执行董事长。在加入白令资本之前，他与他人共同创立了生命科学风险投资公司Helix Ventures并担任其普通合伙人，此前曾担任RMI Partners的管理合伙人和资产管理公司的合伙人。他此前还曾担任多家私营和公共生物技术和医疗技术公司的董事会成员。Zaytsev博士拥有阿尔泰州立医科大学普通医学博士学位、阿尔泰州立医科大学生理学博士学位和斯坦福大学商学院工商管理硕士学位。董事会认为，Zaytsev博士在生命科学风险投资和生物技术投资方面的丰富经验，以及他在私营和上市公司董事会的背景，使他有资格担任董事会成员。
Evgeny Zaytsev has been a member of the Board of Directors since July 2026. He currently serves on the board of directors of several private biotechnology and medical technology companies. Since April 2020, Dr. Zaytsev has served as the co founder and managing partner of Bering Capital. From May 2020 to September 2021, Dr. Zaytsev was co founder and executive chairman of Altesa BioSciences, Inc. Prior to Bering Capital, he co founded and was a general partner of Helix Ventures, a life sciences venture capital firm, and previously held the roles of managing partner of RMI Partners and partner of Asset Management Company. He has also previously served as a member of the board of directors of several private and public biotechnology and medical technology companies. Dr. Zaytsev holds an M.D. in General Medicine from Altai State Medical University, a Ph.D. in Physiology from Altai State Medical University, and an M.B.A. from Stanford Graduate School of Business. The Board of Directors believes that Dr. Zaytsev's extensive experience in life science venture capital and biotechnology investing, as well as his background on private and public company boards, qualifies him to serve on the Board of Directors. - Evgeny Zaytsev自2026年7月起担任董事会成员。他目前担任多家私营生物技术和医疗技术公司的董事会成员。自2020年4月起，Zaytsev博士担任白令资本的联合创始人和管理合伙人。2020年5月至2021年9月，Zaytsev博士为Altesa BioSciences，Inc.的联合创始人兼执行董事长。在加入白令资本之前，他与他人共同创立了生命科学风险投资公司Helix Ventures并担任其普通合伙人，此前曾担任RMI Partners的管理合伙人和资产管理公司的合伙人。他此前还曾担任多家私营和公共生物技术和医疗技术公司的董事会成员。Zaytsev博士拥有阿尔泰州立医科大学普通医学博士学位、阿尔泰州立医科大学生理学博士学位和斯坦福大学商学院工商管理硕士学位。董事会认为，Zaytsev博士在生命科学风险投资和生物技术投资方面的丰富经验，以及他在私营和上市公司董事会的背景，使他有资格担任董事会成员。
- Evgeny Zaytsev has been a member of the Board of Directors since July 2026. He currently serves on the board of directors of several private biotechnology and medical technology companies. Since April 2020, Dr. Zaytsev has served as the co founder and managing partner of Bering Capital. From May 2020 to September 2021, Dr. Zaytsev was co founder and executive chairman of Altesa BioSciences, Inc. Prior to Bering Capital, he co founded and was a general partner of Helix Ventures, a life sciences venture capital firm, and previously held the roles of managing partner of RMI Partners and partner of Asset Management Company. He has also previously served as a member of the board of directors of several private and public biotechnology and medical technology companies. Dr. Zaytsev holds an M.D. in General Medicine from Altai State Medical University, a Ph.D. in Physiology from Altai State Medical University, and an M.B.A. from Stanford Graduate School of Business. The Board of Directors believes that Dr. Zaytsev's extensive experience in life science venture capital and biotechnology investing, as well as his background on private and public company boards, qualifies him to serve on the Board of Directors.
高管简历
中英对照 | 中文 | 英文- Stephen Bardin
Stephen Bardin自2022年8月16日起担任ATAI Life Sciences N.V.的首席财务官，并于2022年6月27日至2022年8月15日担任ATAI Life Sciences N.V.的副首席财务官和候任首席财务官。在加入副总裁之前，Bardin先生曾在商业阶段的生物制药公司“BridgeBio”副总裁担任过各种职务，最近一次是在2022年1月至2022年6月期间担任财务和运营副总裁，之前担任财务和运营副总裁，2020年7月至2021年12月，2019年10月至2020年6月担任财务和运营高级总监。在此之前，Bardin先生在生物制药公司Myovant Sciences Ltd.担任越来越多的职责，最近的职位是2019年1月至2019年10月的企业发展总监，以及2017年7月至2018年12月的企业发展副总监。在此之前，Bardin先生于2011年8月至2014年5月和2016年9月至2017年7月担任波士顿咨询集团的顾问。Bardin先生在斯坦福大学商学院获得工商管理硕士学位，在杜克大学获得生物医学工程理学学士学位。
Stephen Bardin has served as Calcimedica, Inc.'s Chief Financial Officer since November 2024 and served as a consultant to the Company from April 2024 to November 2024. Prior to that he served as the Chief Financial Officer of ATAI Life Sciences N.V. (Nasdaq: ATAI) ("Atai"), a clinical stage biopharmaceutical company, from August 2022 to February 2024, and provided certain transition services to Atai through March 2024. He also served as Atai's Deputy Chief Financial Officer and Chief Financial Officer Designate from June 27, 2022 to August 15, 2022. Prior to joining Atai, Mr. Bardin served in various capacities at BridgeBio Pharma, Inc. ("BridgeBio"), a commercial stage biopharmaceutical company, most recently as its Senior Vice President, Finance and Operations, from January 2022 to June 2022, and previously as Vice President, Finance and Operations, from July 2020 to December 2021, and as Senior Director, Finance and Operations, from October 2019 to June 2020. Prior to that, Mr. Bardin served in roles of increasing responsibility at Myovant Sciences Ltd., a biopharmaceutical company, most recently as Director, Corporate Development from January 2019 to October 2019, and as Associate Director, Corporate Development from July 2017 to December 2018. Prior to that, Mr. Bardin served as a Consultant at The Boston Consulting Group from August 2011 to May 2014 and September 2016 to July 2017. Mr. Bardin received his Master of Business Administration from the Stanford Graduate School of Business and his Bachelor of Science in Engineering in biomedical engineering from Duke University.- Stephen Bardin自2022年8月16日起担任ATAI Life Sciences N.V.的首席财务官，并于2022年6月27日至2022年8月15日担任ATAI Life Sciences N.V.的副首席财务官和候任首席财务官。在加入副总裁之前，Bardin先生曾在商业阶段的生物制药公司“BridgeBio”副总裁担任过各种职务，最近一次是在2022年1月至2022年6月期间担任财务和运营副总裁，之前担任财务和运营副总裁，2020年7月至2021年12月，2019年10月至2020年6月担任财务和运营高级总监。在此之前，Bardin先生在生物制药公司Myovant Sciences Ltd.担任越来越多的职责，最近的职位是2019年1月至2019年10月的企业发展总监，以及2017年7月至2018年12月的企业发展副总监。在此之前，Bardin先生于2011年8月至2014年5月和2016年9月至2017年7月担任波士顿咨询集团的顾问。Bardin先生在斯坦福大学商学院获得工商管理硕士学位，在杜克大学获得生物医学工程理学学士学位。
- Stephen Bardin has served as Calcimedica, Inc.'s Chief Financial Officer since November 2024 and served as a consultant to the Company from April 2024 to November 2024. Prior to that he served as the Chief Financial Officer of ATAI Life Sciences N.V. (Nasdaq: ATAI) ("Atai"), a clinical stage biopharmaceutical company, from August 2022 to February 2024, and provided certain transition services to Atai through March 2024. He also served as Atai's Deputy Chief Financial Officer and Chief Financial Officer Designate from June 27, 2022 to August 15, 2022. Prior to joining Atai, Mr. Bardin served in various capacities at BridgeBio Pharma, Inc. ("BridgeBio"), a commercial stage biopharmaceutical company, most recently as its Senior Vice President, Finance and Operations, from January 2022 to June 2022, and previously as Vice President, Finance and Operations, from July 2020 to December 2021, and as Senior Director, Finance and Operations, from October 2019 to June 2020. Prior to that, Mr. Bardin served in roles of increasing responsibility at Myovant Sciences Ltd., a biopharmaceutical company, most recently as Director, Corporate Development from January 2019 to October 2019, and as Associate Director, Corporate Development from July 2017 to December 2018. Prior to that, Mr. Bardin served as a Consultant at The Boston Consulting Group from August 2011 to May 2014 and September 2016 to July 2017. Mr. Bardin received his Master of Business Administration from the Stanford Graduate School of Business and his Bachelor of Science in Engineering in biomedical engineering from Duke University.
- A. Rachel Leheny
A. Rachel Leheny，自2019年9月起担任CalciMedica首席执行官和董事会成员。Leheny博士是CalciMedica的前董事会主席。Leheny博士自2012年以来一直是Valence Life Sciences的创始董事总经理。Leheny博士是Dalcor Pharmaceuticals的董事会成员，曾在Anthera制药公司和Corthera公司担任董事。此外，2006年6月至2014年3月，Leheny博士担任Caxton Advantage Venture Partners的创始董事总经理。2000年4月至2002年6月，她担任雷曼兄弟生物技术研究团队的负责人。1998年4月至2000年4月，Leheny博士领导瑞银华宝的生物技术研究团队，在此之前的1993年4月至1998年4月，她在Hambrecht & Quist工作，担任董事总经理和高级生物技术分析师。2007年，Leheny博士成为Clearity基金会的创始董事会成员，并在2015年3月至2017年2月期间担任Clearity的临时首席运营官。Leheny博士拥有哈佛大学化学学士学位和哥伦比亚大学化学博士学位。她在加州大学伯克利分校做博士后工作，在那里她是美国国立卫生研究院的研究员和讲师。
A. Rachel Leheny has served as Calcimedica, Inc.'s Chief Executive Officer and a member of the Board of Directors since March 2023. Prior to that, she served as Private CalciMedica's Chief Executive Officer and a member of its board of directors from September 2019 to March 2023. Dr. Leheny has been a founding managing director of Valence Life Sciences since 2012. Dr. Leheny previously served on the board of directors of Dalcor Pharmaceuticals from June 2020 to January 2024 and previously served on the boards of directors of Anthera Pharmaceuticals, Inc. and Corthera, Inc. Additionally, from June 2006 to March 2014, Dr. Leheny served as a founding managing director of Caxton Advantage Venture Partners. From April 2000 to June 2002, she was head of the biotechnology research team at Lehman Brothers. From April 1998 to April 2000, Dr. Leheny headed the biotechnology research team at UBS Warburg and, before that, from April 1993 to April 1998, she worked at Hambrecht & Quist, as managing director and senior biotechnology analyst. In 2007, Dr. Leheny became a founding board member of the Clearity Foundation and served as interim chief operating officer of Clearity from March 2015 to February 2017. Dr. Leheny holds an A.B. in Chemistry from Harvard University and a Ph.D. in Chemistry from Columbia University. She did post doctoral work at the University of California at Berkeley, where she was a National Institutes of Health fellow and lecturer.- A. Rachel Leheny，自2019年9月起担任CalciMedica首席执行官和董事会成员。Leheny博士是CalciMedica的前董事会主席。Leheny博士自2012年以来一直是Valence Life Sciences的创始董事总经理。Leheny博士是Dalcor Pharmaceuticals的董事会成员，曾在Anthera制药公司和Corthera公司担任董事。此外，2006年6月至2014年3月，Leheny博士担任Caxton Advantage Venture Partners的创始董事总经理。2000年4月至2002年6月，她担任雷曼兄弟生物技术研究团队的负责人。1998年4月至2000年4月，Leheny博士领导瑞银华宝的生物技术研究团队，在此之前的1993年4月至1998年4月，她在Hambrecht & Quist工作，担任董事总经理和高级生物技术分析师。2007年，Leheny博士成为Clearity基金会的创始董事会成员，并在2015年3月至2017年2月期间担任Clearity的临时首席运营官。Leheny博士拥有哈佛大学化学学士学位和哥伦比亚大学化学博士学位。她在加州大学伯克利分校做博士后工作，在那里她是美国国立卫生研究院的研究员和讲师。
- A. Rachel Leheny has served as Calcimedica, Inc.'s Chief Executive Officer and a member of the Board of Directors since March 2023. Prior to that, she served as Private CalciMedica's Chief Executive Officer and a member of its board of directors from September 2019 to March 2023. Dr. Leheny has been a founding managing director of Valence Life Sciences since 2012. Dr. Leheny previously served on the board of directors of Dalcor Pharmaceuticals from June 2020 to January 2024 and previously served on the boards of directors of Anthera Pharmaceuticals, Inc. and Corthera, Inc. Additionally, from June 2006 to March 2014, Dr. Leheny served as a founding managing director of Caxton Advantage Venture Partners. From April 2000 to June 2002, she was head of the biotechnology research team at Lehman Brothers. From April 1998 to April 2000, Dr. Leheny headed the biotechnology research team at UBS Warburg and, before that, from April 1993 to April 1998, she worked at Hambrecht & Quist, as managing director and senior biotechnology analyst. In 2007, Dr. Leheny became a founding board member of the Clearity Foundation and served as interim chief operating officer of Clearity from March 2015 to February 2017. Dr. Leheny holds an A.B. in Chemistry from Harvard University and a Ph.D. in Chemistry from Columbia University. She did post doctoral work at the University of California at Berkeley, where she was a National Institutes of Health fellow and lecturer.
- Eric W. Roberts
Eric W. Roberts，自2020年5月起担任CalciMedica首席商务官和董事会成员，并担任副董事长。自2012年以来，罗伯茨一直是Valence Life Sciences的创始董事总经理。罗伯茨先生还是Valence Investments SPV IV、Valence Investments SPV V和Valence Investments SPV VI的创始成员。此外，从2006年6月至2019年12月，罗伯茨先生担任Caxton Advantage Venture Partners的创始董事总经理。从2015年到2019年10月，罗伯茨在VIVUS，Inc.的董事会任职，该公司曾是一家上市生物制药公司。罗伯茨先生曾于2012年6月担任Invuity公司董事会成员，直至2018年10月将其出售给史赛克公司，并于2008年7月担任Gemin X Pharmaceuticals公司董事会成员，直至2012年3月将其出售给Cephalon, Inc.（现为梯瓦制药有限公司）。从1986年到2004年，罗伯茨担任过多种投资银行家的职务，包括2000年4月至2004年1月担任雷曼兄弟医疗保健投资银行部门联席主管，1989年4月至2000年4月担任Dillon，Read & Co. Inc.董事总经理兼合伙人，1986年6月至1989年4月担任花旗公司并购和风险投资部门成员。罗伯茨拥有宾夕法尼亚大学沃顿商学院经济学学士学位。
Eric W. Roberts has served as Calcimedica, Inc.'s Chief Business Officer and member of the Board of Directors since March 2023. Prior to that, he served as Private CalciMedica's Chief Business Officer and a member of its board of directors and its vice chairman from May 2020 to March 2023. Mr. Roberts has been a founding managing director of Valence Life Sciences since 2012. Mr. Roberts is also a founding member of Valence Investments SPV IV, Valence Investments SPV V and Valence Investments SPV VI. Additionally, from June 2006 to December 2019, Mr. Roberts served as a founding managing director of Caxton Advantage Venture Partners. From June 2015 to October 2019, Mr. Roberts served on the board of directors of VIVUS, Inc., a former publicly traded biopharmaceutical company. Mr. Roberts previously served as a member of the board of directors of Invuity, Inc. from June 2012 until its sale to Stryker Corporation in October 2018 and as a member of the board of directors of Gemin X Pharmaceuticals, Inc. from July 2008 until its sale to Cephalon, Inc. (now Teva Pharmaceutical Industries Ltd.) in March 2012. From 1986 to 2004, Mr. Roberts served in a variety of roles as an investment banker, including as co head of the healthcare investment banking group at Lehman Brothers from April 2000 to January 2004, managing director and partner at Dillon, Read & Co. Inc. from April 1989 to April 2000 and a member of Citicorp's mergers and venture capital groups from June 1986 to April 1989. Mr. Roberts holds a B.S. in Economics from The Wharton School of the University of Pennsylvania.- Eric W. Roberts，自2020年5月起担任CalciMedica首席商务官和董事会成员，并担任副董事长。自2012年以来，罗伯茨一直是Valence Life Sciences的创始董事总经理。罗伯茨先生还是Valence Investments SPV IV、Valence Investments SPV V和Valence Investments SPV VI的创始成员。此外，从2006年6月至2019年12月，罗伯茨先生担任Caxton Advantage Venture Partners的创始董事总经理。从2015年到2019年10月，罗伯茨在VIVUS，Inc.的董事会任职，该公司曾是一家上市生物制药公司。罗伯茨先生曾于2012年6月担任Invuity公司董事会成员，直至2018年10月将其出售给史赛克公司，并于2008年7月担任Gemin X Pharmaceuticals公司董事会成员，直至2012年3月将其出售给Cephalon, Inc.（现为梯瓦制药有限公司）。从1986年到2004年，罗伯茨担任过多种投资银行家的职务，包括2000年4月至2004年1月担任雷曼兄弟医疗保健投资银行部门联席主管，1989年4月至2000年4月担任Dillon，Read & Co. Inc.董事总经理兼合伙人，1986年6月至1989年4月担任花旗公司并购和风险投资部门成员。罗伯茨拥有宾夕法尼亚大学沃顿商学院经济学学士学位。
- Eric W. Roberts has served as Calcimedica, Inc.'s Chief Business Officer and member of the Board of Directors since March 2023. Prior to that, he served as Private CalciMedica's Chief Business Officer and a member of its board of directors and its vice chairman from May 2020 to March 2023. Mr. Roberts has been a founding managing director of Valence Life Sciences since 2012. Mr. Roberts is also a founding member of Valence Investments SPV IV, Valence Investments SPV V and Valence Investments SPV VI. Additionally, from June 2006 to December 2019, Mr. Roberts served as a founding managing director of Caxton Advantage Venture Partners. From June 2015 to October 2019, Mr. Roberts served on the board of directors of VIVUS, Inc., a former publicly traded biopharmaceutical company. Mr. Roberts previously served as a member of the board of directors of Invuity, Inc. from June 2012 until its sale to Stryker Corporation in October 2018 and as a member of the board of directors of Gemin X Pharmaceuticals, Inc. from July 2008 until its sale to Cephalon, Inc. (now Teva Pharmaceutical Industries Ltd.) in March 2012. From 1986 to 2004, Mr. Roberts served in a variety of roles as an investment banker, including as co head of the healthcare investment banking group at Lehman Brothers from April 2000 to January 2004, managing director and partner at Dillon, Read & Co. Inc. from April 1989 to April 2000 and a member of Citicorp's mergers and venture capital groups from June 1986 to April 1989. Mr. Roberts holds a B.S. in Economics from The Wharton School of the University of Pennsylvania.
- Michael J. Dunn
Michael J. Dunn于2013年加入CalciMedica，担任公司发展高级副总裁，自2014年起担任总裁兼首席运营官，并于2014年至2020年5月担任CalciMedica董事会成员。邓恩先生是Arisan Therapeutics的董事会成员，曾于2012年至2017年担任Aegea Biotechnologies的董事会成员。2010年至2013年，邓恩先生担任Biocept, Inc.企业发展高级副总裁。在此之前，他曾担任Monogram Biosciences公司副总裁兼首席商务官，该公司于2009年被Laboratory Corporation of America Holdings（d/b/a LabCorp）收购。从2003年4月到2004年12月，邓恩先生通过与ViroLogic公司的合并担任ACLARA BioSciences公司的首席商务官；合并后的实体随后更名为Monogram Biosciences公司。从2002年3月到2003年4月，邓恩先生担任生物技术公司ActivX Biosciences，Inc.的业务发展执行副总裁，并帮助设计了与日本Kyorin Pharmaceuticals，Co. Ltd.的合作伙伴关系，后者于次年收购了ActivX Biosciences，Inc.。1998年7月至2002年3月，邓恩先生担任生物技术工具公司Aurora Biosciences Corporation的业务发展副总裁，该公司被福泰制药收购。从1995年到1998年，邓恩先生担任上市公司SIBIA Neurosciences，Inc.的业务发展副总裁，从1984年到1994年，担任前身公司SIBIA，Inc.的业务发展总监。邓恩先生拥有圣迭戈大学的工商管理硕士学位和芝加哥大学的生物学学士学位。
Michael J. Dunn has served as Calcimedica, Inc.'s President and Chief Operating Officer since the closing of the Merger in March 2023. Prior to that he served as the President and Chief Operating Officer of Private CalciMedica from 2014 to March 2023, and as its Senior Vice President, Corporate Development from 2013 to 2014. Mr. Dunn also served as a member of Private CalciMedica's board of directors from 2014 to May 2020. Mr. Dunn serves on the board of directors of Arisan Therapeutics and previously served on the board of directors of Aegea Biotechnologies from 2012 to 2017. From 2010 to 2013, Mr. Dunn was senior vice president, corporate development at Biocept, Inc. Prior to that, he served as vice president and chief business officer of Monogram Biosciences, Inc., which was acquired by Laboratory Corporation of America Holdings (d/b/a LabCorp) in 2009. From April 2003 to December 2004, Mr. Dunn was chief business officer for ACLARA BioSciences, Inc., through its merger with ViroLogic, Inc.; the combined entity subsequently changed its name to Monogram Biosciences, Inc. From March 2002 to April 2003, Mr. Dunn served as executive vice president of business development for ActivX Biosciences, Inc., a biotechnology company, and helped engineer a partnership with Kyorin Pharmaceuticals, Co. Ltd. of Japan, which acquired ActivX Biosciences, Inc. the following year. From July 1998 to March 2002, Mr. Dunn was vice president of business development for Aurora Biosciences Corporation, a biotechnology tools company, through its acquisition by Vertex Pharmaceuticals. From 1995 to 1998, Mr. Dunn was vice president of business development for SIBIA Neurosciences, Inc., a publicly traded company, and, from 1984 to 1994, was director of business development at the predecessor company, SIBIA, Inc. Mr. Dunn holds an M.B.A. from the University of San Diego and a bachelor's degree in Biology from the University of Chicago.- Michael J. Dunn于2013年加入CalciMedica，担任公司发展高级副总裁，自2014年起担任总裁兼首席运营官，并于2014年至2020年5月担任CalciMedica董事会成员。邓恩先生是Arisan Therapeutics的董事会成员，曾于2012年至2017年担任Aegea Biotechnologies的董事会成员。2010年至2013年，邓恩先生担任Biocept, Inc.企业发展高级副总裁。在此之前，他曾担任Monogram Biosciences公司副总裁兼首席商务官，该公司于2009年被Laboratory Corporation of America Holdings（d/b/a LabCorp）收购。从2003年4月到2004年12月，邓恩先生通过与ViroLogic公司的合并担任ACLARA BioSciences公司的首席商务官；合并后的实体随后更名为Monogram Biosciences公司。从2002年3月到2003年4月，邓恩先生担任生物技术公司ActivX Biosciences，Inc.的业务发展执行副总裁，并帮助设计了与日本Kyorin Pharmaceuticals，Co. Ltd.的合作伙伴关系，后者于次年收购了ActivX Biosciences，Inc.。1998年7月至2002年3月，邓恩先生担任生物技术工具公司Aurora Biosciences Corporation的业务发展副总裁，该公司被福泰制药收购。从1995年到1998年，邓恩先生担任上市公司SIBIA Neurosciences，Inc.的业务发展副总裁，从1984年到1994年，担任前身公司SIBIA，Inc.的业务发展总监。邓恩先生拥有圣迭戈大学的工商管理硕士学位和芝加哥大学的生物学学士学位。
- Michael J. Dunn has served as Calcimedica, Inc.'s President and Chief Operating Officer since the closing of the Merger in March 2023. Prior to that he served as the President and Chief Operating Officer of Private CalciMedica from 2014 to March 2023, and as its Senior Vice President, Corporate Development from 2013 to 2014. Mr. Dunn also served as a member of Private CalciMedica's board of directors from 2014 to May 2020. Mr. Dunn serves on the board of directors of Arisan Therapeutics and previously served on the board of directors of Aegea Biotechnologies from 2012 to 2017. From 2010 to 2013, Mr. Dunn was senior vice president, corporate development at Biocept, Inc. Prior to that, he served as vice president and chief business officer of Monogram Biosciences, Inc., which was acquired by Laboratory Corporation of America Holdings (d/b/a LabCorp) in 2009. From April 2003 to December 2004, Mr. Dunn was chief business officer for ACLARA BioSciences, Inc., through its merger with ViroLogic, Inc.; the combined entity subsequently changed its name to Monogram Biosciences, Inc. From March 2002 to April 2003, Mr. Dunn served as executive vice president of business development for ActivX Biosciences, Inc., a biotechnology company, and helped engineer a partnership with Kyorin Pharmaceuticals, Co. Ltd. of Japan, which acquired ActivX Biosciences, Inc. the following year. From July 1998 to March 2002, Mr. Dunn was vice president of business development for Aurora Biosciences Corporation, a biotechnology tools company, through its acquisition by Vertex Pharmaceuticals. From 1995 to 1998, Mr. Dunn was vice president of business development for SIBIA Neurosciences, Inc., a publicly traded company, and, from 1984 to 1994, was director of business development at the predecessor company, SIBIA, Inc. Mr. Dunn holds an M.B.A. from the University of San Diego and a bachelor's degree in Biology from the University of Chicago.
- Sudarshan Hebbar
Sudarshan Hebbar自2017年4月起担任CalciMedica首席医疗官，此前曾于2015年11月至2017年4月担任临床开发高级副总裁。2015年1月至2015年10月，Hebbar博士担任马林克罗制药的顾问，担任全球多中心4期试验的临床开发负责人。2013年7月至2014年6月，他担任Thrasos Innovation肾脏科副总裁。从2013年7月到2013年10月，赫巴尔博士在免疫诊断公司Oncimmune Holdings plc担任医学副总裁和美国董事会成员。在加入Oncimmune之前，Hebbar博士曾在上市的生物制药公司Reata制药公司担任医学总监。Hebbar博士在雅培开始了他的行业生涯，在那里他担任高级医学主任。在加入雅培之前，Hebbar博士是透析诊所公司的医学主任和堪萨斯城肾脏协会的合伙人。赫巴尔博士拥有约翰霍普金斯大学自然科学学士学位和杜兰大学医学院医学博士学位。他在亨内平县医疗中心完成了内科住院医师实习和重症医学研究金，在芝加哥大学完成了肾脏病学研究金，在芝加哥大学麦克林临床医学伦理学中心完成了临床医学伦理学研究金。
Sudarshan Hebbar has served as Calcimedica, Inc.'s Chief Medical Officer since the closing of the Merger in March 2023. Prior to that, he served in various roles at Private CalciMedica including as its Chief Medical Officer from April 2017 to March 2023, its Senior Vice President of Clinical Development, from November 2015 to April 2017, and as a consultant from June 2014 to November 2015. From January 2015 to October 2015, Dr. Hebbar was a consultant for Mallinckrodt Pharmaceuticals, where he served as the clinical development lead for a global multicenter Phase 4 trial. From July 2013 to June 2014, he was the vice president of nephrology at Thrasos Innovation. From July 2013 to October 2013, Dr. Hebbar served as medical vice president and a member of the U.S. board of directors at Oncimmune Holdings plc, an immunodiagnostics company. Before joining Oncimmune, Dr. Hebbar served as a medical director at Reata Pharmaceuticals, Inc., a publicly traded biopharmaceutical company. Dr. Hebbar began his industry career at Abbott Laboratories, where he served as a senior medical director. Prior to joining Abbott Laboratories, Dr. Hebbar was a medical director at Dialysis Clinics Incorporated and a partner at Kidney Associates of Kansas City. Dr. Hebbar holds a B.A. in Natural Sciences from The Johns Hopkins University and an M.D. from Tulane University School of Medicine. He completed a residency in Internal Medicine and a fellowship in Critical Care Medicine, both at Hennepin County Medical Center, a fellowship in Nephrology at the University of Chicago and a fellowship in Clinical Medical Ethics at The Maclean Center for Clinical Medical Ethics at the University of Chicago.- Sudarshan Hebbar自2017年4月起担任CalciMedica首席医疗官，此前曾于2015年11月至2017年4月担任临床开发高级副总裁。2015年1月至2015年10月，Hebbar博士担任马林克罗制药的顾问，担任全球多中心4期试验的临床开发负责人。2013年7月至2014年6月，他担任Thrasos Innovation肾脏科副总裁。从2013年7月到2013年10月，赫巴尔博士在免疫诊断公司Oncimmune Holdings plc担任医学副总裁和美国董事会成员。在加入Oncimmune之前，Hebbar博士曾在上市的生物制药公司Reata制药公司担任医学总监。Hebbar博士在雅培开始了他的行业生涯，在那里他担任高级医学主任。在加入雅培之前，Hebbar博士是透析诊所公司的医学主任和堪萨斯城肾脏协会的合伙人。赫巴尔博士拥有约翰霍普金斯大学自然科学学士学位和杜兰大学医学院医学博士学位。他在亨内平县医疗中心完成了内科住院医师实习和重症医学研究金，在芝加哥大学完成了肾脏病学研究金，在芝加哥大学麦克林临床医学伦理学中心完成了临床医学伦理学研究金。
- Sudarshan Hebbar has served as Calcimedica, Inc.'s Chief Medical Officer since the closing of the Merger in March 2023. Prior to that, he served in various roles at Private CalciMedica including as its Chief Medical Officer from April 2017 to March 2023, its Senior Vice President of Clinical Development, from November 2015 to April 2017, and as a consultant from June 2014 to November 2015. From January 2015 to October 2015, Dr. Hebbar was a consultant for Mallinckrodt Pharmaceuticals, where he served as the clinical development lead for a global multicenter Phase 4 trial. From July 2013 to June 2014, he was the vice president of nephrology at Thrasos Innovation. From July 2013 to October 2013, Dr. Hebbar served as medical vice president and a member of the U.S. board of directors at Oncimmune Holdings plc, an immunodiagnostics company. Before joining Oncimmune, Dr. Hebbar served as a medical director at Reata Pharmaceuticals, Inc., a publicly traded biopharmaceutical company. Dr. Hebbar began his industry career at Abbott Laboratories, where he served as a senior medical director. Prior to joining Abbott Laboratories, Dr. Hebbar was a medical director at Dialysis Clinics Incorporated and a partner at Kidney Associates of Kansas City. Dr. Hebbar holds a B.A. in Natural Sciences from The Johns Hopkins University and an M.D. from Tulane University School of Medicine. He completed a residency in Internal Medicine and a fellowship in Critical Care Medicine, both at Hennepin County Medical Center, a fellowship in Nephrology at the University of Chicago and a fellowship in Clinical Medical Ethics at The Maclean Center for Clinical Medical Ethics at the University of Chicago.
- Kenneth A. Stauderman
Kenneth A. Stauderman是CalciMedica的联合创始人之一，自2017年4月起担任首席科学官，此前曾于2014年8月至2017年4月担任研发高级副总裁，并于2007年4月至2014年8月担任研发副总裁。从2000年到2007年，施陶德曼博士是TorreyPines Therapeutics（f/k/a Neurogenetics，Inc.）的生物学和主要发现执行总监。在加入TorreyPines Therapeutics之前，Stauderman博士于1994年至2000年在SIBIA Neurosciences，Inc.（后来成为圣迭戈的默沙东研究实验室）担任分子和细胞生物学主任，并于1986年至1994年在Marion Merrell Dow Pharmaceuticals担任高级科学家。施陶德曼博士拥有弗吉尼亚大学心理学学士学位和德克萨斯大学圣安东尼奥健康科学中心药理学博士学位。
Kenneth A. Stauderman has served as Calcimedica, Inc.'s Chief Scientific Officer since the closing of the Merger in March 2023. Dr. Stauderman is one of Private CalciMedica's co founders and served as its Chief Scientific Officer from April 2017 to March 2023, and previously served as its Senior Vice President of Research and Development, from August 2014 to April 2017, and as its Vice President of Research, from April 2007 to August 2014. From 2000 to 2007, Dr. Stauderman was executive director of biology and lead discovery at TorreyPines Therapeutics (f/k/a Neurogenetics, Inc.). Prior to TorreyPines Therapeutics, Dr. Stauderman was director of molecular and cell biology at SIBIA Neurosciences, Inc. (which later became Merck Research Laboratories, San Diego) from 1994 to 2000, and senior scientist at Marion Merrell Dow Pharmaceuticals from 1986 to 1994. Dr. Stauderman holds a B.A. in Psychology from the University of Virginia and a Ph.D. in Pharmacology from the University of Texas Health Science Center at San Antonio.- Kenneth A. Stauderman是CalciMedica的联合创始人之一，自2017年4月起担任首席科学官，此前曾于2014年8月至2017年4月担任研发高级副总裁，并于2007年4月至2014年8月担任研发副总裁。从2000年到2007年，施陶德曼博士是TorreyPines Therapeutics（f/k/a Neurogenetics，Inc.）的生物学和主要发现执行总监。在加入TorreyPines Therapeutics之前，Stauderman博士于1994年至2000年在SIBIA Neurosciences，Inc.（后来成为圣迭戈的默沙东研究实验室）担任分子和细胞生物学主任，并于1986年至1994年在Marion Merrell Dow Pharmaceuticals担任高级科学家。施陶德曼博士拥有弗吉尼亚大学心理学学士学位和德克萨斯大学圣安东尼奥健康科学中心药理学博士学位。
- Kenneth A. Stauderman has served as Calcimedica, Inc.'s Chief Scientific Officer since the closing of the Merger in March 2023. Dr. Stauderman is one of Private CalciMedica's co founders and served as its Chief Scientific Officer from April 2017 to March 2023, and previously served as its Senior Vice President of Research and Development, from August 2014 to April 2017, and as its Vice President of Research, from April 2007 to August 2014. From 2000 to 2007, Dr. Stauderman was executive director of biology and lead discovery at TorreyPines Therapeutics (f/k/a Neurogenetics, Inc.). Prior to TorreyPines Therapeutics, Dr. Stauderman was director of molecular and cell biology at SIBIA Neurosciences, Inc. (which later became Merck Research Laboratories, San Diego) from 1994 to 2000, and senior scientist at Marion Merrell Dow Pharmaceuticals from 1986 to 1994. Dr. Stauderman holds a B.A. in Psychology from the University of Virginia and a Ph.D. in Pharmacology from the University of Texas Health Science Center at San Antonio.